Literature DB >> 23594602

Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage.

Maria Manczak1, P Hemachandra Reddy.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative mental illness characterized by memory loss, multiple cognitive impairments, and changes in personality and behavior. The purpose of our study was to determine the interaction between monomeric and oligomeric amyloid-β (Aβ) and phosphorylated tau in AD neurons. Using postmortem brains from AD patients at different stages of disease progression and control subjects, and also from AβPP, AβPPxPS1, and 3xTg-AD mice, we studied the physical interaction between Aβ and phosphorylated tau. Using immunohistological and double-immunofluorescence analyses, we also studied the localization of monomeric and oligomeric Aβ with phosphorylated tau. We found monomeric and oligomeric Aβ interacted with phosphorylated tau in neurons affected by AD. Further, these interactions progressively increased with the disease process. These findings led us to conclude that Aβ interacts with phosphorylated tau and may damage neuronal structure and function, particularly synapses, leading to cognitive decline in AD patients. Our findings suggest that binding sites between Aβ and phosphorylated tau need to be identified and molecules developed to inhibit this interaction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23594602      PMCID: PMC3943249          DOI: 10.3233/JAD-130275

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  30 in total

1.  Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins.

Authors:  Xinglong Wang; Bo Su; Sandra L Siedlak; Paula I Moreira; Hisashi Fujioka; Yang Wang; Gemma Casadesus; Xiongwei Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-02       Impact factor: 11.205

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 3.  Pathways linking Abeta and tau pathologies.

Authors:  Frank M LaFerla
Journal:  Biochem Soc Trans       Date:  2010-08       Impact factor: 5.407

4.  Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.

Authors:  Heng Du; Lan Guo; Shiqiang Yan; Alexander A Sosunov; Guy M McKhann; Shirley ShiDu Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

5.  Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease.

Authors:  Jian-Ping Guo; Tetsuaki Arai; Judit Miklossy; Patrick L McGeer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

6.  Tau reduction prevents Abeta-induced defects in axonal transport.

Authors:  Keith A Vossel; Kai Zhang; Jens Brodbeck; Aaron C Daub; Punita Sharma; Steven Finkbeiner; Bianxiao Cui; Lennart Mucke
Journal:  Science       Date:  2010-09-09       Impact factor: 47.728

Review 7.  Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline.

Authors:  P Hemachandra Reddy; Maria Manczak; Peizhong Mao; Marcus J Calkins; Arubala P Reddy; Ulziibat Shirendeb
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Impaired balance of mitochondrial fission and fusion in Alzheimer's disease.

Authors:  Xinglong Wang; Bo Su; Hyoung-gon Lee; Xinyi Li; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

Review 9.  Intracellular amyloid-beta in Alzheimer's disease.

Authors:  Frank M LaFerla; Kim N Green; Salvatore Oddo
Journal:  Nat Rev Neurosci       Date:  2007-07       Impact factor: 34.870

10.  Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.

Authors:  Reisuke H Takahashi; Estibaliz Capetillo-Zarate; Michael T Lin; Teresa A Milner; Gunnar K Gouras
Journal:  Neurobiol Aging       Date:  2008-09-03       Impact factor: 4.673

View more
  30 in total

1.  Structure-based inhibitors of amyloid beta core suggest a common interface with tau.

Authors:  Sarah L Griner; Paul Seidler; Jeannette Bowler; Kevin A Murray; Tianxiao Peter Yang; Shruti Sahay; Michael R Sawaya; Duilio Cascio; Jose A Rodriguez; Stephan Philipp; Justyna Sosna; Charles G Glabe; Tamir Gonen; David S Eisenberg
Journal:  Elife       Date:  2019-10-15       Impact factor: 8.140

Review 2.  Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

Authors:  Ramesh Kandimalla; Vani Thirumala; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-08-25       Impact factor: 5.187

Review 3.  Structural evaluations of tau protein conformation: methodologies and approaches.

Authors:  Nicole L Zabik; Matthew M Imhof; Sanela Martic-Milne
Journal:  Biochem Cell Biol       Date:  2017-03-09       Impact factor: 3.626

4.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

Review 5.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

Review 6.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

7.  Cerebrovascular disorders caused by hyperfibrinogenaemia.

Authors:  Nino Muradashvili; Reeta Tyagi; Neetu Tyagi; Suresh C Tyagi; David Lominadze
Journal:  J Physiol       Date:  2016-06-16       Impact factor: 5.182

8.  Garrison Institute on Aging: A New Hope for Elderly Individuals and Patients with Alzheimer's Disease.

Authors:  P Hemachandra Reddy; Joan Blackmon; Veronica Molinar-Lopez; Clay Ament; Maria Manczak; Ramesh Kandimalla; Xianglin Yin; Akhilesh Pandey; Chandra Sekhar Kuruva; Rui Wang; David Fry; Carrah Osborn; Kathleen Stonum; Kandi Quesada; Ruben Gonzales; Annette Boles
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

9.  Anxiety-like behavior as an early endophenotype in the TgF344-AD rat model of Alzheimer's disease.

Authors:  Nathan S Pentkowski; Laura E Berkowitz; Shannon M Thompson; Emma N Drake; Carlos R Olguin; Benjamin J Clark
Journal:  Neurobiol Aging       Date:  2017-10-05       Impact factor: 4.673

Review 10.  Synergy between amyloid-β and tau in Alzheimer's disease.

Authors:  Marc Aurel Busche; Bradley T Hyman
Journal:  Nat Neurosci       Date:  2020-08-10       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.